Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’ Substack by Magnus Ofstad. In this ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

(Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...

“Our pipeline is broadening. I think that is an important part of thinking about the future of Merck beyond 2028,” said Dr.

Guggenheim analyst Vamil Divan lowered the firm’s price target on Merck (MRK) to $122 from $130 and keeps a Buy rating on the shares. The firm ...

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...

Merck accelerates subcutaneous Keytruda rollout to protect cancer drug's dominance as IV patent nears 2028 expiry.